Therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: A double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial

Cancer

Volumn 115, Issue 16, 2009, Pages 3699-3708

  Hong, Gyun Wu ^a   Si, Yeol Song ^b   Yeon, Sil Kim ^c   Young, Taek Oh ^d   Chang, Geol Lee ^e   Ki, Chang Keum ^e   Yong, Chan Ahn ^f   Lee, Sang Wook ^b  

^a Seoul National University College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Ajou University School of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Chemotherapy; EGF; Head and neck cancer; Mucositis; Radiotherapy

Indexed keywords

CISPLATIN; PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADULT; AGED; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; EPIDERMAL GROWTH FACTOR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; PLACEBOS; RADIATION INJURIES; RECOMBINANT PROTEINS; STOMATITIS;

EID: 68549113047     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24414     Document Type: Article

References (52)

1. Sutherland SE, Browman GP. Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys. 2001;49:917-930.
2. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685-1690.
3. Vokes EE, Haraf DJ, Kies MS. The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol. 2000;27:34-38.
4. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88:890-899.
5. Fung K, Lyden TH, Lee J, et al. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys. 2005;63:1395-1399.
6. Parsons JT, Bova FJ, Million RR. A re-evaluation of split-course technique for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1980;6:1645-1652.
7. Alden ME, O'Reilly RC, Topham A, Lowry LD, Brodovsky H, Curran WJ Jr. Elapsed radiation therapy treatment time as a predictor of survival in patients with advanced head and neck cancer who receive chemotherapy and radiation therapy. Radiology. 1996;201:675-680.
8. Garden AS. Mucositis: current management and investigations. Semin Radiat Oncol. 2003;13:267-273.
9. Carter DL, Hebert ME, Smink K, Leopold KA, Clough RL, Brizel DM. Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. Head Neck. 1999;21:760-766.
10. Cengiz M, Ozyar E, Ozturk D, Akyol F, Atahan IL, Hayran M. Sucralfate in the prevention of radiation-induced oral mucositis. J Clin Gastroenterol. 1999;28:40-43.
11. Teo PM, Kwan WH, Leung SF, et al. Early tumour response and treatment toxicity after hyperfractionated radiotherapy in nasopharyngeal carcinoma. Br J Radiol. 1996;69:241-248.
12. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47:1-12.
13. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123-136.
14. Dorr W, Jacubek A, Kummermehr J, Herrmann T, Dölling-Jochem I, Eckelt U. Effects of stimulated repopulation on oral mucositis during conventional radiotherapy. Radiother Oncol. 1995;37:100-107.
15. Dorr W, Hamilton CS, Boyd T, Reed B, Denham JW. Radiation-induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys. 2002;52:911-917.
16. Dorr W, Emmendorfer H, Haide E, Kummermehr J. Proliferation equivalent of 'accelerated repopulation' in mouse oral mucosa. Int J Radiat Biol. 1994;66:157-167.
17. Dorr W, Kummermehr J. Proliferation kinetics of mouse tongue epithelium under normal conditions and following single dose irradiation. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60:287-294.
18. Plevova P. Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review. Oral Oncol. 1999;35:453-470.
19. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J Biol Chem. 1962;237:1555-1562.
20. Savage CR, Jr, Inagami T, Cohen S. The primary structure of epidermal growth factor. J Biol Chem. 1972;247:7612-7621.
21. Gregory H. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature. 1975;257:325-327.
22. Gresik EW, van der Noen H, Barka T. Epidermal growth factor-like material in rat submandibular gland. Am J Anat. 1979;156:83-89.
23. Weaver LT, Gonnella PA, Israel EJ, Walker WA. Uptake and transport of epidermal growth factor by the small intestinal epithelium of the fetal rat. Gastroenterology. 1990;98: 828-837.
24. Cohen S. The epidermal growth factor (EGF). Cancer. 1983;51:1787-1791.
25. Steidler NE, Reade PC. Histomorphological effects of epidermal growth factor on skin and oral mucosa in neonatal mice. Arch Oral Biol. 1980;25:37-43.
26. Waterfield MD.Epidermal growth factor and related molecules. Lancet. 1989:1243-1246.
27. Ino M, Ushiro K, Ino C, Yamashita T, Kumazawa T. Kinetics of epidermal growth factor in saliva. Acta Otolaryngol Suppl. 1993;500:126-130.
28. Thesleff I, Viinikka L, Saxen L, Lehtonen E, Perheentupa J. The parotid gland is the main source of human salivary epidermal growth factor. Life Sci. 1988;43:13-18.
29. Epstein JB, Emerton S, Guglietta A. Assessment of epidermal growth factor in oral secretions of patients receiving radiation therapy for cancer. Oral Oncol. 1997;33:359-363.
30. Carpenter G. Epidermal growth factor is a major growth-promoting agent in human milk. Science. 1980;210:198-199.
31. Heitz PU, Kasper M, van Noorden S, Polak JM, Gregory H, Pearse AG. Immunohistochemical localisation of urogastrone to human duodenal and submandibular glands. Gut. 1978;19:408-413.
32. Olsen PS, Poulsen SS, Therkelsen K, Nexø E. Effect of sialoadenectomy and synthetic human urogastrone on healing of chronic gastric ulcers in rats. Gut. 1986;27:1443-1449.
33. Procaccino F, Reinshagen M, Hoffmann P, et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology. 1994;107:12-17.
34. Noguchi S, Ohba Y, Oka T. Effect of salivary epidermal growth factor on wound healing of tongue in mice. Am J Physiol. 1991;260:E620-625.
35. Girdler NM, McGurk M, Aqual S, Prince M. The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration. A phase I clinical trial. Am J Clin Oncol. 1995;18:403-406.
36. Lee SW, Jung KI, Kim YW, Jung HD, Kim HS, Hong JP. Effect of epidermal growth factor against radiotherapy-induced oral mucositis in rats. Int J Radiat Oncol Biol Phys. 2007;67:1172-1178.
37. Lee KK, Jo HJ, Lee S-W, et al. Recombinant human epidermal growth factor accelerates recovery of mouse small intestinal mucosa after radiation damage. Int J Radiat Biol Oncol Phys. 2008;71:1230-1235.
38. Kaanders JH, van der Kogel AJ, Ang KK. Altered fractionation: limited by mucosal reactions?Radiother Oncol. 1999;50:247-260.
39. Dorr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol. 2001;61:223-231.
40. Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol. 2003;69:161-168.
41. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39-43.
42. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg. 2006;56:394-400.
43. Kim JH, Chu FC, Lakshmi V, Houde R. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol. 1986;9:132-134.
44. Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J Radiat Oncol Biol Phys. 1989;16:1571-1575.
45. Barker G, Loftus L, Cuddy P, Barker B. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol. 1991;71:288-293.
46. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys. 2006;64:684-691.
47. Masucci G, Broman P, Kelly C, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Med Oncol. 2005;22:247-256.
48. Barnes DW. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J Cell Biol. 1982;93:1-4.
49. Christen RD, Hom DK, Porter DC, et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest. 1990;86:1632-1640.
50. Gill GN, Lazar CS. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature. 1981;293:305-307.
51. Imai Y, Leung CK, Friesen HG, Shiu RP. Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. Cancer Res. 1982;42:4394-4398.
52. Kamata N, Chida K, Rikimaru K, Horikoshi M, Enomoto S, Kuroki T. Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture. Cancer Res. 1986;46:1648-1653.